首页 | 本学科首页   官方微博 | 高级检索  
     检索      


Characterization of nanochannel delivery membrane systems for the sustained release of resveratrol and atorvastatin: new perspectives on promoting heart health
Authors:Juliana Sih  Shyam S Bansal  Stefano Filipini  Silvia Ferrati  Kunal Raghuwansi  Erika Zabre  Eugenia Nicolov  Daniel Fine  Mauro Ferrari  Ganesh Palapattu  Alessandro Grattoni
Institution:1. Department of Nanomedicine, The Methodist Hospital Research Institute, 6670 Bertner Ave., Room # R8-216, Houston, TX, 77030, USA
2. NanoMedical Systems, Inc, Austin, TX, 77030, USA
3. Department of Medicine, Weill Cornell Medical College, New York, NY, 10065, USA
4. Department of Bioengineering, Rice University, Houston, TX, 77005, USA
5. Alliance for NanoHealth, Houston, TX, 77030, USA
6. Department of Urology, University of Michigan, Ann Arbor, MI, USA
Abstract:Novel drug delivery systems capable of continuous sustained release of therapeutics have been studied extensively for use in the prevention and management of chronic diseases. The use of these systems holds promise as a means to achieve higher patient compliance while improving therapeutic index and reducing systemic toxicity. In this work, an implantable nanochannel drug delivery system (nDS) is characterized and evaluated for the long-term sustained release of atorvastatin (ATS) and trans-resveratrol (t-RES), compounds with a proven role in managing atherogenic dyslipidemia and promoting cardioprotection. The primary mediators of drug release in the nDS are nanofluidic membranes with hundreds of thousands of nanochannels (up to 100,000/mm2) that attain zero-order release kinetics by exploiting nanoconfinement and molecule-to-surface interactions that dominate diffusive transport at the nanoscale. These membranes were characterized using gas flow analysis, acetone diffusion, and scanning and transmission electron microscopy (SEM, TEM). The surface properties of the dielectric materials lining the nanochannels, SiO2 and low-stress silicon nitride, were further investigated using surface charge analysis. Continuous, sustained in vitro release for both ATS and t-RES was established for durations exceeding 1 month. Finally, the influence of the membranes on cell viability was assessed using human microvascular endothelial cells. Morphology changes and adhesion to the surface were analyzed using SEM, while an MTT proliferation assay was used to determine the cell viability. The nanochannel delivery approach, here demonstrated in vitro, not only possesses all requirements for large-scale high-yield industrial fabrication, but also presents the key components for a rapid clinical translation as an implantable delivery system for the sustained administration of cardioprotectants.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号